Upload
others
View
10
Download
0
Embed Size (px)
Citation preview
OEM
Customized Biomaterials Development & Manufacturing
Living ImmunoassayExcellence
2 Customized Biomaterials. Development & Manufacturing
Werfen is a growing, family-owned, innovative company founded in 1966 in Barcelona, Spain. Our OEM Technology Center has consolidated experience in research, development and manufacturing of customized assays and biomaterials. We offer end-to-end solutions for the IVD industry with the most innovative capabilities to enhance competitiveness and time-to-market.
Our mission is to become your partner of choice as a center of excellence in providing innovative end-to-end OEM solutions (products & services) to IVD companies.
Innovation
Our OEM Technology Center ranks among the top centers of excellence for immunoassay and biomaterial development and manufacturing in the industry. Our focus on technological advances ensures our customers access to state-of-the-art R&D and manufacturing capabilities. Werfen’s innovative nature is strengthened through close relationships with prestigious universities and biotechnology research centers around the world.
Operational Excellence
Our key strength is the combination of the ongoing effort to improve our organizational processes, products and services with the Werfen mindset that embraces principles and tools to create a sustainable partnership with our customers and employees.Our Quality System is certified to ISO 13485:2016 / EN ISO 13485:2016 as well as MDSAP.
Commitment
Customers and patients benefit from the efficiency of a talented global team of qualified and specialized professionals who lend their enthusiasm, dedication and energy on a daily basis in order to provide high quality products & services.
3 Customized Biomaterials. Development & Manufacturing
You can rely on the expertise and capabilities of our R&D and Operations
teams to develop and manufacture customized Biomaterials
> 200 Biomaterials
developed
> 10 differentclinical fields
Use on commercial WW assays
6 Customized Biomaterials. Development & Manufacturing
DesignBased on your needs we can design the entire process for generating a new recombinant antibody.
If you already have an antibody in mind, we can modify it to meet your needs: improving affinity, sequence modification, tag addition, etc. Our expertise in recombinant antibodies extends to different antibody formats. If your needs are related to a specific antigen, we can also design the entire generation and production process for this new recombinant antigen or we can modify an existing one by improving affinity, sequence modification, tag addition, improving stability, among others. In addition, we have in-house bioinformatics protein modelling to simulate how the biomateiral could be affected in different conditions.
One of the major challenges for an IVD company is to obtain IgM-positive plasma and serum to be used as controls or calibrators for diagnostic assays since IgMs have a short life, disappearing earlier than IgGs. In order to overcome this challenge, our customized biomaterials team has developed a process to generate a recombinant IgM antibody that can be used as a calibrator or control for a diagnostic assay.
Figure 1. Summary of the process of generating an IgM antibody to be used as a calibrator or control
7 Customized Biomaterials. Development & Manufacturing
ScreeningIn this step of the process, the most appropriate expression systems are screened based on production yield, protein performance, stability, binding kinetics and cell viability.
At the end of the screening step we can select the ideal strain/clone that would produce the biomaterial that will best meet your needs.
Figure 1. Summary of the process of generating an IgM antibody to be used as a calibrator or control
Our current R&D expertise and our current operations use the following biomaterial sources to produce the biomaterials needed to supply assays covering a wide range of clinical fields to customers worldwide.
Microbial strains:
Recombinant antigens
Hybridomacell lines:
Monoclonal antibodies against
viral & human antigens
Mammaliancell lines:
Viral & human antigens
Baculovirus expression systems:
Viral & human antigens
Native: Viral, human
& mammalian antigens.
Polyclonal antibodies
Yeast:Recombinant antibodies &
antigens
8 Customized Biomaterials. Development & Manufacturing
Purification & Characterization Our extraction & purification platforms are optimized taking in consideration that the purified antibody/protein will be used in a diagnostic assay. Based on your needs, we can perform peptide mapping analysis, evaluate state of aggregation, as well as determining your sample molecular weight distribution, purity, charge variants and glycosylation patterns among others.
Figure 2. Example of Peptide Mapping (PEM).
5.0 10.0 15.0 20.0 25.0 30.0 35.0 40.0 45.0 50.0 55.0 60.0 65.0 70.0 75.0 80.0 min
uVrIgG + tagrIgG Hybridoma IgG
9 Customized Biomaterials. Development & Manufacturing
The characterization process of bioma-terials to be used in diagnostic products is key to understanding and managing posttranslational modification variants, along with process and product related impurities. This approach is crucial for product con-sistency and quality. One of our customers requested that our customized biomaterials team characterize a full IgG antibody from hybridoma, and a new recombinant IgG antibody (designed as an alternative for the full IgG antibody from hybridoma). As you can see in Figure 2, the peptide mapping done by our customized biomaterials team ensured that both the hybridoma and recombinant IgG molecules ultimately presented a similar tryptic profile.
During the process of producing an antibody, the glycosylation pattern must be understood in order to assess the performance and reproducibility of the selected antibody. Our biomaterials team did the analysis of the glycosylation pattern (Figure 3) of a full IgG monoclonal antibody and a F(ab’)2 fragment from the same hybridoma. The objective of this analysis was to optimize the cell culture and the purification conditions of that monoclonal antibody and its F(ab’)2 fragment.
Figure 3. Example of Hydrophilic Interaction Chromatography (HILIC) to assess glycosylation pattern.
0.0 2.5 5.0 7.5 10.0 12.5 15.0 17.5 20.0 22.5 25.0 27.5 30.0 32.5 35.0 37.5 40.0 42.5 45.0 47.5 50.0 52.5 55.0 57.5 60.0 62.5 min
10.0 12.5 15.0 17.5 20.0 22.5 25.0 27.5 30.0 32.5 35.0 37.5 40.0 min
220000
210000
200000
190000
180000
170000
160000
150000
140000
130000
120000
110000
100000
90000
80000
70000
60000
50000
40000
30000
20000
10000
0
-10000
uV
25000
22500
20000
17500
15000
12500
10000
7500
5000
2500
0
uV
0.0 2.5 5.0 7.5 10.0 12.5 15.0 17.5 20.0 22.5 25.0 27.5 30.0 32.5 35.0 37.5 40.0 42.5 45.0 47.5 50.0 52.5 55.0 57.5 60.0 62.5 min
13.0 14.0 15.0 16.0 17.0 18.0 19.0 20.0 21.0 22.0 23.0 24.0 25.0 26.0 27.0 28.0 29.0 30.0 31.0 32.0 33.0 34.0 35.0 36.0 37.0 38.0 39.0 40.0 41.0 42.0 min
17000001650000160000015500001500000145000014000001350000130000012500001200000115000011000001050000100000095000090000085000080000075000070000065000060000055000050000045000040000035000030000025000020000015000010000050000
0-50000
1200001150001100001050001000009500090000850008000075000700006500060000550005000045000400003500030000250002000015000100005000
0-5000
uV uVHybridoma F(ab’)2Hybridoma IgG
N-Glycan analysis
Hybridoma IgGHybridoma F(ab’)2
O-Glycan analysis
PNGase F
10 Customized Biomaterials. Development & Manufacturing
Moreover, functional tests for the requested biomaterial can be provided. These tests include affinity constants and interaction kinetics by biolayer interferogram and surface plasmon resonance as well as diagnostic assays.
Apart from Bio-Layer interferometry and surface plasmon resonance, our biomaterials can benefit from R&D assay development to assess the functionality of a new biomaterial in latex based or chemiluminiscence based immunoassays.
11 Customized Biomaterials. Development & Manufacturing
Process Optimization& Scale-up
The strategy for process scale up is selected based on your operational demands. When scaling up, an optimization process is needed in order to improve productivity and streamline supply chain operations.
When facing a production process optimization and scale-up, our biomaterials team (a co-team of biotecnhology R&D and Manufacturing) takes into consideration the improvement of the protein or antibody expression system and optimization of the culture conditions to increase the specific production of the biomaterial for diagnostics.
Once the production process is optimized it can be scaled up to the optimal production system such as a bioreactor up to 100L.
12 Customized Biomaterials. Development & Manufacturing
Figure 4. Example of a manufacturing processs optimization and scale-up: In the graph on left Size Exclusion Chromatogra-phy for the analysis of the recombinant antigens obtained with curent and optimized manufacturing proceprocess and a elec-tronic microscopy image of the recombiant antigens obtained after the manufacturing process optimization and scale-up.
Our biomaterials team works towards the goal of streamlining biomaterials production so as to optimize and scale up the production process for a biomaterial for diagnostics. In figure 4 you can see a couple of examples of the results obtained after the manufacturing process optimization and scale-up to bioreactior of a recombinant viral antigen (virus like particles) to be used for a diagnostic assay to detect antibodies.
mAU20019519018518017517016516015515014514013513012512011511010510095908580757065605550454035302520151050
-5ml
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25
Optimized manufacturing process for recombinant AntigenCurrent manufacturing process for recombinant AntigenInjection
13 Customized Biomaterials. Development & Manufacturing
ManufacturingWerfen’s state-of-the-art production facilities can adapt to your supply needs thanks to their capabilities:
We have the biomaterial supply chain integrated in the same building, this allows us to being able to secure the supply to our partners. Note that in the midst of the 2020 WW health crisis, during the first half of the year we were able to supply more than 20 different Biomaterial references to more than 15 different IVD companies located worldwide.
35,000 m2 (376,736 ft2) facilities, including 9,200 m2 (99,000 ft2) dedicated to production activities
State-of-the-art equipment: Bioreactors, AKTA Systems among others
More than 200 product dedicated purification columns
Positive-and negative-pressure laboratories
Biosafety level 2 laboratories
Production under GMP procedures
Final QC, physicochemical and functional analysis
14 Customized Biomaterials. Development & Manufacturing
With Werfen’s CustomizedBiomaterials you can get access to
Downstream Capabilities
Biomaterial Sources In-Process Controls
MonoclonalAntibodies
Hybridorna Cell Lines
Mammalian cell lines (recAb)
PolyclonalAntibodies
Goat
Rabbit
Guinea Pig
RecombinantProteins
Microbial Strains
Mammalian Cell Lines
Baculovirus Expression System
Yeast
Viable and total cells concentration by automatic cell counter
Nutrients and byproducts analysis
Cell populationanalysis
Cell culture aminoacid analysis
Protein Purification
Protein Extraction
Centrifugation & Ultracentrifugation
Microfiltration & Ultrafiltration
Chromatography (Affinity, IEX, SEC, HIC, Multimodal)
Protein refolding
Chemical modification
Labeling
Protein Characterization
Physicochemical Analysis
UV Spectrophotometry
Electrophoresis
Isoelectric point determination
Ion exchange chromatography
Glycosytation pattern
Peptide mapping
Protein amino acid analysis
Surface hydrophobicity
DSF (differential scanning fluorimetry)
Functional Analysis
Surface plasmon resonance
Bio-Layer Interferometry
Enzyme-Linked Immunosorbent Assay (ELISA)
Chemilluminescent Immunoassay
Latex based immunoassay
NativeAntigens
Bacteria
Viruses
Human Sera
Upstream Capabilities
15 Customized Biomaterials. Development & Manufacturing
Thanks to our collaborations with innovative companies, academic institutions and research centers, the following techniques are available to characterize your biomaterial of interest.
Our facilities are located in Llicà d’Amunt, Barcelona and cover more than 35,000 m2 (376,736 ft2). Contact us at [email protected] to discuss your customized Biomaterial needs and request a call back.
Functional Analysis
Surface plasmon resonance
Bio-Layer Interferometry
Enzyme-Linked Immunosorbent Assay (ELISA)
Chemilluminescent Immunoassay
Latex based immunoassay
MassSpectrometry
Protein & DNA sequencing
Higher Order structure analysis (Circulardichroism & IR spectrophotometry)
ElectronMicroscopy
PeptideSynthesis
Epitopemapping
Differential Scanning Calorimetry
3100
-980
3 R0
1 SE
PTEM
BER-
2021
Can Malé08186 Lliçà d’AmuntBarcelona, SpainPhone: +34-93-860-9000werfen.com/oem
Living ImmunoassayExcellence